Author:
Cassioli Chiara,Capitani Nagaja,Staton Claire C.,Schirra Claudia,Finetti Francesca,Onnis Anna,Alawar Nadia,Tu Szu-Min,Lopresti Ludovica,Tatangelo Vanessa,Tangredi Carmela,Valvo Salvatore,Chang Hsin-Fang,Miccoli Annachiara,Compeer Ewaldus B.,Nicholls Jemma,Blazar Bruce,Marotta Giuseppe,Wood Matthew J. A.,Trentin Livio,Patrussi Laura,Dustin Michael L.,Becherer Ute,Baldari Cosima T.
Abstract
AbstractSupramolecular Attack Particles (SMAPs) are particulate entities, characterized by a cytotoxic core enriched in granzymes and perforin surrounded by a glycoproteic shell, released by CTLs and NK cells. Prior proteomic analysis identified thrombospondin-1 (TSP-1) and thrombospondin-4 (TSP-4) as putative components of SMAPs. While TSP-1 has been validated as a component of the SMAP shell and shown to contribute significantly to CTL-mediated killing, the expression and function of TSP-4 in CTLs, and its interplay with TSP-1 in SMAP biogenesis and function, has not been investigated as yet. Here we demonstrate that TSP-4 and TSP-1 have a complementary expression profile during in vitro human CD8+T cell differentiation to CTLs and sequentially localize to lytic granules (LG), with TSP-4 being required for TSP-1 association with LGs. Correlative light microscopy identified the TSP-enriched LGs as the SMAP-containing multicore granules. We show by STED microscopy a heterogeneity among TSP-enriched LGs, the most abundant population being positive for both TSP-4 and TSP-1. We also show that TSP-1 and TSP-4 are co-released in association with SMAPs at immune synapses formed on planar supported lipid bilayers, as assessed by dSTORM imaging. Finally, we provide evidence that TSP-4 is required for CTL- and SMAP-mediated cell killing. Of note, we found that chronic lymphocytic leukemia (CLL) cell supernatants, which suppress CTL mediated killing, also suppress expression of TSP-4 as well as of cytolytic effectors and impair SMAP biogenesis. These results identify TSP-4 as a key player in SMAP structure and activity and suggest that SMAPs may be a new target for immune suppression by CLL.
Publisher
Cold Spring Harbor Laboratory